

Raw Sequence Listing
Patent Application US/07/599,543E12/17/91
13:43:49

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Opperman, Hermann
Ozkaynak, Engin
Rueger, David C.
Kuberasampath, Thangavel
- (ii) TITLE OF INVENTION: Osteogenic Proteins
- (iii) NUMBER OF SEQUENCES: 11
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Testa Hurwitz & Thibeault
 - (B) STREET: 53 State Street
 - (C) CITY: Boston
 - (D) STATE: Massachusetts
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 02109
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette, 3.50 inch, 720 kb storage
 - (B) COMPUTER: IBM XT
 - (C) OPERATING SYSTEM: DOS 3.30
 - (D) SOFTWARE: ASC II
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 07/599,543
 - (B) FILING DATE: 18-Oct-90
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 569,920
 - (B) FILING DATE: 20-Aug-90
 - (C) APPLICATION NUMBER: US 315,342
 - (D) FILING DATE: 23-Feb-89
 - (E) APPLICATION NUMBER: US 422,699
 - (F) FILING DATE: 17-Oct-89

Patent Application US/07/599,543E

54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69 (2) INFORMATION FOR SEQ ID NO:1:
70 (i) SEQUENCE CHARACTERISTICS:
71 (A) LENGTH: 139 amino acids
72 (B) TYPE: amino acid
73 (D) TOPOLOGY: linear
74 (ii) MOLECULE TYPE: protein
75 (ix) FEATURE:
76 (A) NAME: mOP2 (mature)
77 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
78
79 Ala Ala Arg Pro Leu Lys Arg Arg Gln
80 1 5
81 Pro Lys Lys Thr Asn Glu Leu Pro His
82 10 15
83 Pro Asn Lys Leu Pro Gly Ile Phe Asp
84 20 25
85 Asp Gly His Gly Ser Arg Gly Arg Glu
86 30 35
87 Val Cys Arg Arg His Glu Leu Tyr Val
88 40 45
89 Arg Phe Arg Asp Leu Gly Trp Leu Asp
90 50
91 Trp Val Ile Ala Pro Gln Gly Tyr Ser
92 55 60
93 Ala Tyr Tyr Cys Glu Gly Glu Cys Ala
94 65 70
95 Phe Pro Leu Asp Ser Cys Met Asn Ala
96 75 80
97 Thr Asn His Ala Ile Leu Gln Ser Leu
98 85 90
99 Val His Leu Met Lys Pro Asp Val Val
100 95
101 Pro Lys Ala Cys Cys Ala Pro Thr Lys
102 100 105
103 Leu Ser Ala Thr Ser Val Leu Tyr Tyr
104 110 115
105
106

107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135 Asp Ser Ser Asn Asn Val Ile Leu Arg
136 120 125
137 Lys His Arg Asn Met Val Val Lys Ala
138 130 135
139 Cys Gly Cys His
140
141

142 (2) INFORMATION FOR SEQ ID NO:2:
143 (i) SEQUENCE CHARACTERISTICS:
144 (A) LENGTH: 1930 base pairs
145 (B) TYPE: nucleic acid
146 (C) STRANDEDNESS: single
147 (D) TOPOLOGY: linear
148 (ii) MOLECULE TYPE: cDNA
149 (iii) HYPOTHETICAL: no
150 (iv) ANTI-SENSE: no
151 (vi) ORIGINAL SOURCE:
152 (A) ORGANISM: mouse
153 (F) TISSUE TYPE: embryo
154 (ix) FEATURE:
155 (A) NAME: mOP2
156 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

157
158 GGAATTCCGC TGCCAGGCAC AGGTGCGCCG TCTGGTCCTC 40
159 CCCGTCTGGC GTCAGCCGAG CCCGACCAGC TACCAGTGGA 80

Patent Application US/07/599,543E

```
160  TCGCGCCCGG CTGAAAGTCC GAG ATG GCT ATG CGT      115
161                      Met Ala Met Arg
162                      1
163  CCC GGG CCA CTC TGG CTA TTG GGC CTT GCT CTG      148
164  Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu
165    5          10          15
166  TGC GCG CTG GGA GGC GGC CAC GGT CCC GGT CCC      181
167  Cys Ala Leu Gly Gly Gly His Gly Pro Gly Pro
168          20          25
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200  CCG CAC ACC TGT CCC CAG CGT CGC CTG GGA GCG      214
201  Pro His Thr Cys Pro Gln Arg Arg Leu Gly Ala
202          30          35
203  CGC GAC CGG GAC ATG CAG CGT GAA ATC CTG CCG      247
204  Arg Asp Arg Asp Met Gln Arg Glu Ile Leu Pro
205    40          45
206  GTG CTC GGG CTA CCG GGA CGC CCC GAC CCC GTG      280
207  Val Leu Gly Leu Pro Gly Arg Pro Asp Pro Val
208    50          55
209  CAC AAC CCG CCG CTG CCC GGC ACG CAG CGT GCG      313
210  His Asn Pro Pro Leu Pro Gly Thr Gln Arg Ala
211    60          65          70
212  CCC CTC TTC ATG TTG GAC CTA TAC CAC GCC ATG      346
```

Patent Application US/07/599,543E

```
213 Pro Leu Phe Met Leu Asp Leu Tyr His Ala Met
214          75          80
215 ACC GAT GAC GAC GAC GGC GGG CCA CCA CAG GCT 379
216 Thr Asp Asp Asp Asp Gly Gly Pro Pro Gln Ala
217          85          90
218 CAC TTA GGC CGT GCC GAC CTG GTC ATG AGC TTC 412
219 His Leu Gly Arg Ala Asp Leu Val Met Ser Phe
220          95          100
221 GTC AAC ATG GTG GAA CGC GAC CGT ACC CTG GGC 445
222 Val Asn Met Val Glu Arg Asp Arg Thr Leu Gly
223          105          110
224 TAC CAG GAG CCA CAC TGG AAG GAA TTC CAC TTT 478
225 Tyr Gln Glu Pro His Trp Lys Glu Phe His Phe
226          115          120          125
227 GAC CTA ACC CAG ATC CCT GCT GGG GAG GCT GTC 511
228 Asp Leu Thr Gln Ile Pro Ala Gly Glu Ala Val
229          130          135
230 ACA GCT GCT GAG TTC CGG ATC TAC AAA GAA CCC 544
231 Thr Ala Ala Glu Phe Arg Ile Tyr Lys Glu Pro
232          140          145
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265 AGC ACC CAC CCG CTC AAC ACA ACC CTC CAC ATC 577
```

Patent Application US/07/599,543E

```
266 Ser Thr His Pro Leu Asn Thr Thr Leu His Ile
267     150           155
268 AGC ATG TTC GAA GTG GTC CAA GAG CAC TCC AAC    610
269 Ser Met Phe Glu Val Val Gln Glu His Ser Asn
270     160           165
271 AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG    643
272 Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gln
273     170           175           180
274 ACG CTC CGA TCT GGG GAC GAG GGC TGG CTG GTG    676
275 Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu Val
276           185           190
277 CTG GAC ATC ACA GCA GCC AGT GAC CGA TGG CTG    709
278 Leu Asp Ile Thr Ala Ala Ser Asp Arg Trp Leu
279           195           200
280 CTG AAC CAT CAC AAG GAC CTG GGA CTC CGC CTC    742
281 Leu Asn His His Lys Asp Leu Gly Leu Arg Leu
282     205           210
283 TAT GTG GAA ACC GCG GAT GGG CAC AGC ATG GAT    775
284 Tyr Val Glu Thr Ala Asp Gly His Ser Met Asp
285     215           220
286 CCT GGC CTG GCT GGT CTG CTT GGA CGA CAA GCA    808
287 Pro Gly Leu Ala Gly Leu Leu Gly Arg Gln Ala
288     225           230           235
289 CCA CGC TCC AGA CAG CCT TTC ATG GTA ACC TTC    841
290 Pro Arg Ser Arg Gln Pro Phe Met Val Thr Phe
291           240           245
292 TTC AGG GCC AGC CAG AGT CCT GTG CGG GCC CCT    874
293 Phe Arg Ala Ser Gln Ser Pro Val Arg Ala Pro
294           250           255
295 CGG GCA GCG AGA CCA CTG AAG AGG AGG CAG CCA    907
296 Arg Ala Ala Arg Pro Leu Lys Arg Arg Gln Pro
297     260           265
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
```

319
320
321
322
323
324
325
326
327
328
329
330 AAG AAA ACG AAC GAG CTT CCG CAC CCC AAC AAA 940
331 Lys Lys Thr Asn Glu Leu Pro His Pro Asn Lys
332 270 275
333 CTC CCA GGG ATC TTT GAT GAT GGC CAC GGT TCC 973
334 Leu Pro Gly Ile Phe Asp Asp Gly His Gly Ser
335 280 285 290
336 CGC GGC AGA GAG GTT TGC CGC AGG CAT GAG CTC 1006
337 Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu
338 295 300
339 TAC GTC AGA TTC CGT GAC CTT GGC TGG CTG GAC 1039
340 Tyr Val Arg Phe Arg Asp Leu Gly Trp Leu Asp
341 305 310
342 TGG GTC ATC GCC CCC CAG GGC TAC TCT GCC TAT 1072
343 Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala Tyr
344 315 320
345 TAC TGT GAG GGG GAG TGT GCT TTC CCA CTG GAC 1105
346 Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp
347 325 330
348 TCC TGT ATG AAC GCC ACC AAC CAT GCC ATC TTG 1138
349 Ser Cys Met Asn Ala Thr Asn His Ala Ile Leu
350 335 340 345
351 CAG TCT CTG GTG CAC CTG ATG AAG CCA GAT GTT 1171
352 Gln Ser Leu Val His Leu Met Lys Pro Asp Val
353 350 355
354 GTC CCC AAG GCA TGC TGT GCA CCC ACC AAA CTG 1204
355 Val Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu
356 360 365
357 AGT GCC ACC TCT GTG CTG TAC TAT GAC AGC AGC 1237
358 Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser
359 370 375
360 AAC AAT GTC ATC CTG CGT AAA CAC CGT AAC ATG 1270
361 Asn Asn Val Ile Leu Arg Lys His Arg Asn Met
362 380 385
363
364
365
366
367
368
369
370
371

372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395 GTG GTC AAG GCC TGT GGC TGC CAC 1294
396 Val Val Lys Ala Cys Gly Cys His
397 390 400
398 TGAGGCCCGG CCCAGCATCC TGCTTCTACT ACCTTACCAT 1334
399 CTGGCCGGGC CCCTCTCCAG AGGCAGAAAC CCTTCTATGT 1374
400 TATCATAGCT CAGACAGGGG CAATGGGAGG CCCTTCACTT 1414
401 CCCCTGGCCA CTTCTGTCTA AAATTCTGGT CTTTCCCAGT 1454
402 TCCTCTGTCC TTCATGGGGT TTCGGGGCTA TCACCCCGCC 1494
403 CTCTCCATCC TCCTACCCCA AGCATAGACT GAATGCACAC 1534
404 AGCATCCCAG AGCTATGCTA ACTGAGAGGT CTGGGGTCAG 1574
405 CACTGAAGGC CCACATGAGG AAGACTGATC CTTGGCCATC 1614
406 CTCAGCCAC AATGGCAAAT TCTGGATGGT CTAAGAAGCC 1654
407 CTGGAATTCT AAACATAGATG ATCTGGGCTC TCTGCACCAT 1694
408 TCATTGTGGC AGTTGGGACA TTTTATAGGTA TAACAGACAC 1734
409 ATACACTTAG ATCAATGCAT CGCTGTACTC CTTGAAATCA 1774
410 GAGCTAGCTT GTTAGAAAAA GAATCAGAGC CAGGTATAGC 1814
411 GGTGCATGTC ATTAATCCCA GCGCTAAAGA GACAGAGACA 1854
412 GGAGAATCTC TGTGAGTTCA AGGCCACATA GAAAGAGCCT 1894
413 GTCTCGGGAG CAGGAAAAAA AAAAAAACG GAATTC 1930
414
415

416 (2) INFORMATION FOR SEQ ID NO:3:
417 (i) SEQUENCE CHARACTERISTICS:
418 (A) LENGTH: 139 amino acids
419 (B) TYPE: amino acid
420 (D) TOPOLOGY: linear
421 (ii) MOLECULE TYPE: protein
422 (ix) FEATURE:
423 (A) NAME: hOP2 (mature)
424 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Raw Sequence Listing
Patent Application US/07/599,543E12/17/91
13:44:21

```
425
426 Ala Val Arg Pro Leu Arg Arg Arg Gln
427 1 5
428 Pro Lys Lys Ser Asn Glu Leu Pro Gln
429 10 15
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462 Ala Asn Arg Leu Pro Gly Ile Phe Asp
463 20 25
464 Asp Val His Gly Ser His Gly Arg Gln
465 30 35
466 Val Cys Arg Arg His Glu Leu Tyr Val
467 40 45
468 Ser Phe Gln Asp Leu Gly Trp Leu Asp
469 50
470 Trp Val Ile Ala Pro Gln Gly Tyr Ser
471 55 60
472 Ala Tyr Tyr Cys Glu Gly Glu Cys Ser
473 65 70
474 Phe Pro Leu Asp Ser Cys Met Asn Ala
475 75 80
476 Thr Asn His Ala Ile Leu Gln Ser Leu
477 85 90
```

478 Val His Leu Met Lys Pro Asn Ala Val
479 95
480 Pro Lys Ala Cys Cys Ala Pro Thr Lys
481 100 105
482 Leu Ser Ala Thr Ser Val Leu Tyr Tyr
483 110 115
484 Asp Ser Ser Asn Asn Val Ile Leu Arg
485 120 125
486 Lys Ala Arg Asn Met Val Val Lys Ala
487 130 135
488 Cys Gly Cys His
489
490

491 (2) INFORMATION FOR SEQ ID NO:4:
492 (i) SEQUENCE CHARACTERISTICS:
493 (A) LENGTH: 1941 base pairs
494 (B) TYPE: nucleic acid
495 (C) STRANDEDNESS: single
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526

527 (D) TOPOLOGY: linear
528 (ii) MOLECULE TYPE: cDNA
529 (iii) HYPOTHETICAL: no
530 (iv) ANTI-SENSE: no

Patent Application US/07/599,543E

531 (vi) ORIGINAL SOURCE:
532 (A) ORGANISM: homo sapiens
533 (F) TISSUE TYPE: hippocampus
534 (ix) FEATURE:
535 (A) NAME: hOP2
536 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
537
538 GGAATTCCGG CCACAGTGGC GCCGGCAGAG CAGGAGTGGC 40
539 TGGAGGAGCT GTGGTTGGAG CAGGAGGTGG CACGGCAGGG 80
540 CTGGAGGGCT CCCTATGAGT GGCGGAGACG GCCCAGGAGG 120
541 CGCTGGAGCA ACAGCTCCCA CACCGCACCA AGCGGTGGCT 160
542 GCAGGAGCTC GCCCATCGCC CCTGCGCTGC TCGGACCGCG 200
543 GCCACAGCCG GACTGGCGGG TACGGCGGCG ACAGAGGCAT 240
544 TGGCCGAGAG TCCCAGTCCG CAGAGTAGCC CCGGCCTCGA 280
545 GGCGGTGGCG TCCCAGTCCCT CTCCGTCCAG GAGCCAGGAC 320
546 AGGTGTGCGG CGGCGGGGCT CCAGGGACCG CGCCTGAGGC 360
547 CGGCTGCCCC CCGTCCCCG CCGCCCCCG CGCCCGCCGC 400
548 CCGCCGAGCC CAGCCTCCTT GCCGTCGGGG CGTCCCCAGG 440
549 CCCTGGGTCG GCCGCGGAGC CGATGCGCGC CCGCTGAGCG 480
550 CCCCAGCTGA GCGCCCCCGG CCTGCC ATG ACC GCG CTC 518
551 Met Thr Ala Leu
552 1
553 CCC GGC CCG CTC TGG CTC CTG GGC CTG GCG CTA 551
554 Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu
555 5 10 15
556 TGC GCG CTG GGC GGG GGC GGC CCC GGC CTG CGA 584
557 Cys Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg
558 20 25
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583

Patent Application US/07/599,543E

584
585
586
587
588
589
590
591
592 CCC CCG CCC GGC TGT CCC CAG CGA CGT CTG GGC 617
593 Pro Pro Pro Gly Cys Pro Gly arg Arg Leu Gly
594 30 35
595 GCG CGC GAC CGG GAC GTG CAG CGC GAG ATC CTG 650
596 Ala Arg Asp Arg Asp Val Gln Arg Glu Ile Leu
597 40 45
598 GCG GTG CTC GGG CTG CCT GGG CGG CCC CGG CCC 683
599 Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro
600 50 55
601 CGC GCG CCA CCC GCC GCC TCC CGG CTG CCC GCG 716
602 Arg Ala Pro Pro Ala Ala Ser Arg Leu Pro Ala
603 60 65 70
604 TCC GCG CCG CTC TTC ATG CTG GAC CTG TAC CAC 749
605 Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr His
606 75 80
607 CGC ATG GCC GGC GAC GAC GAC GAG GAC GGC GCC 782
608 Arg Met Ala Gly Asp Asp Asp Glu Asp Gly Ala
609 85 90
610 GCG GAG GCC CTG GGC CGC GCC GAC CTG GTC ATG 815
611 Ala Glu Ala Leu Gly Arg Ala Asp Leu Val Met
612 95 100
613 AGC TTC GTT AAC ATG GTG GAG CGA GAC CGT GCC 848
614 Ser Phe Val Asn Met Val Glu Arg Asp Arg Ala
615 105 110
616 CTG GGC CAC CAG GAG CCC CAT TGG AAG GAG TTC 881
617 Leu Gly His Gln Glu Pro His Trp Lys Glu Phe
618 115 120 125
619 CGC TTT GAC CTG ACC CAG ATC CCG GCT GGG GAG 914
620 Arg Phe Asp Leu Thr Gln Ile Pro Ala Gly Glu
621 130 135
622 GCG GTC ACA GCT GCG GAG TTC CGG ATT TAC AAG 947
623 Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys
624 140 145
625
626
627
628
629
630
631
632
633
634
635
636

637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657 GTG CCC AGC ATC CAC CTG CTC AAC AGG ACC CTC 980
658 Val Pro Ser Ile His Leu Leu Asn Arg Thr Leu
659 150 155
660 CAC GTC AGC ATG TTC CAG GTG GTC CAG GAG CAG 1013
661 His Val Ser Met Phe Gln Val Val Gln Glu Gln
662 160 165
663 TCC AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT 1046
664 Ser Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp
665 170 175 180
666 CTT CAG ACG CTC CGA GCT GGA GAC GAG GGC TGG 1079
667 Leu Gln Thr Leu Arg Ala Gly Asp Glu Gly Trp
668 185 190
669 CTG GTG CTG GAT GTC ACA GCA GCC AGT GAC TGC 1112
670 Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys
671 195 200
672 TGG TTG CTG AAG CGT CAC AAG GAC CTG GGA CTC 1145
673 Trp Leu Leu Lys Arg His Lys Asp Leu Gly Leu
674 205 210
675 CGC CTC TAT GTG GAG ACT GAG GAC GGG CAC AGC 1178
676 Arg Leu Tyr Val Glu Thr Glu Asp Gly His Ser
677 215 220
678 GTG GAT CCT GGC CTG GCC GGC CTG CTG GGT CAA 1211
679 Val Asp Pro Gly Leu Ala Gly Leu Leu Gly Gln
680 225 230 235
681 CGG GCC CCA CGC TCC CAA CAG CCT TTC GTG GTC 1244
682 Arg Ala Pro Arg Ser Gln Gln Pro Phe Val Val
683 240 245
684 ACT TTC TTC AGG GCC AGT CCG AGT CCC ATC CGC 1277
685 Thr Phe Phe Arg Ala Ser Pro Ser Pro Ile Arg
686 250 255
687 ACC CCT CGG GCA GTG AGG CCA CTG AGG AGG AGG 1310
688 Thr Pro Arg Ala Val Arg Pro Leu Arg Arg Arg
689 260 265

690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722 CAG CCG AAG AAA AGC AAC GAG CTG CCG CAG GCC 1343
723 Gln Pro Lys Lys Ser Asn Glu Leu Pro Gln Ala
724 270 275
725 AAC CGA CTC CCA GGG ATC TTT GAT GAC GTC CAC 1376
726 Asn Arg Leu Pro Gly Ile Phe Asp Asp Val His
727 280 285 290
728 GGC TCC CAC GGC CGG CAG GTC TGC CGT CGG CAC 1409
729 Gly Ser His Gly Arg Gln Val Cys Arg Arg His
730 295 300
731 GAG CTC TAC GTC AGC TTC CAG GAC CTC GGC TGG 1442
732 Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp
733 305 310
734 CTG GAC TGG GTC ATC GCT CCC CAA GGC TAC TCG 1475
735 Leu Asp Trp Val Ile Ala Pro Gln Gly Tyr Ser
736 315 320
737 GCC TAT TAC TGT GAG GGG GAG TGC TCC TTC CCA 1508
738 Ala Tyr Tyr Cys Glu Gly Glu Cys Ser Phe Pro
739 325 330
740 CTG GAC TCC TGC ATG AAT GCC ACC AAC CAC GCC 1541
741 Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala
742 335 340 345

Patent Application US/07/599,543E

743 ATC CTG CAG TCC CTG GTG CAC CTG ATG AAG CCA 1574
744 Ile Leu Gln Ser Leu Val His Leu Met Lys Pro
745 350 355
746 AAC GCA GTC CCC AAG GCG TGC TGT GCA CCC ACC 1607
747 Asn Ala Val Pro Lys Ala Cys Cys Ala Pro Thr
748 360 365
749 AAG CTG AGC GCC ACC TCT GTG CTC TAC TAT GAC 1640
750 Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp
751 370 375
752 AGC AGC AAC AAC GTC ATC CTG CGC AAA GCC CGC 1673
753 Ser Ser Asn Asn Val Ile Leu Arg Lys Ala Arg
754 380 385
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787 AAC ATG GTG GTC AAG GCC TGC GGC TGC CAC 1703
788 Asn Met Val Val Lys Ala Cys Gly Cys His
789 390 395
790 TGAGTCAGCC CGCCCAGCCC TACTGCAGCA ATTCACTGGC 1743
791 CGTCGTTTTA CAACGTGTGA CTGGGAAAAC CCTGGCGTTA 1783
792 CCCAACTTAA TCGCCTTGCA GCACATCCCC CTTTCGCCAG 1823
793 CTGGCTAATA GCGAAGAGGC CCCGCACCGA TCGCCCTTCC 1863
794 CAACAGTTGC GCCCCAGTGA ATGGCGAATG GCAAATTGTA 1903
795 AGCGTTAATA TTTTGTTAAA ATTCGCGTTA AATTTTTT 1941

796
797
798 (2) INFORMATION FOR SEQ ID NO:5:
799 (i) SEQUENCE CHARACTERISTICS:
800 (A) LENGTH: 98 amino acids
801 (B) TYPE: amino acid
802 (D) TOPOLOGY: linear
803 (ii) MOLECULE TYPE: protein
804 (ix) FEATURE:
805 (D) OTHER INFORMATION: wherein "res."
806 means "residue" and Xaa at res. 2 = (Lys or Arg); Xaa at
807 res.3 = (Lys or Arg); Xaa res.9 = (Ser or Arg); Xaa at
808 res.11 = (Arg or Gln); Xaa at res.16 = (Gln or Leu); Xaa
809 at res. 19 = (Ile or Val); Xaa at res.23 = (Glu or Gln);
810 Xaa at res.26 = (Ala or Ser); Xaa at res. 34 = (Ala or
811 or Ser); Xaa at res.38= (Asn or Asp); Xaa at res. 40 =
812 (Tyr or Cys); Xaa at res.49 = (Val or Leu); Xaa at
813 res.52= (His or Asn); Xaa at res. 53 = (Phe or
814 Leu); Xaa at res. 54 = (Ile or Met); Xaa at res. 55 = (Asn
815 or Lys); Xaa at res. 56 = (Glu, Asp or Asn); Xaa at res.
816 57=(Thr, Ala or Val); Xaa at res. 61 = (Pro or Ala);
817 Xaa at res. 67=(gln or Lys); Xaa at res. 69 =
818 (Asn or Ser); Xaa at 71=(Ile or Thr); Xaa at res.
819 76= (Phe or Tyr); Xaa at res. 78 = (Asp, Glu or Ser);
820 Xaa at res. 80= (Ser or Asn); Xaa at res. 84 = (Ile or
821 Asp); Xaa at res. 85 Arg); Xaa at res. 87 = (Tyr, Ala
822 or His); and Xaa at res. 93=(Arg or Lys)
823

824 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
825
826 Cys Xaa Xaa His Glu Leu Tyr Val Xaa Phe
827 1 5 10
828 Xaa Asp Leu Gly Trp Xaa Asp Trp Xaa Ile
829 15 20
830 Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys
831 25 30
832 Glu Gly Cys Xaa Phe Pro Leu Xaa Ser Xaa
833 35 40
834 Met Asn Ala Thr Asn His Ala Ile Xaa Thr
835 45 50
836 Leu Xaa Xaa Xaa Xaa Xaa Xaa Val
837 55
838 Pro Lys Xaa Cys Cys Ala Pro Thr Xaa Leu
839 60 65
840
841
842
843
844
845
846
847
848

849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901

Xaa Ala Xaa Ser Val Leu Tyr Xaa Asp
70 75
Xaa Ser Xaa Asn Val Xaa Leu Xaa Lys
80 85
Xaa Pro Asn Met Val Val Xaa Ala Cys Gly
90 95
Cys His

- (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 437 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:

902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919 (A) ORGANISM: Human
920 (F) TISSUE TYPE: placenta
921 (ix) FEATURE:
922 (A) NAME: OP1
923 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
924
925 TCC ACG GGG 9
926 Ser Thr Gly
927 1
928 AGC AAA CAG CGC AGC CAG AAC CGC TCC AAG ACG 42
929 Ser Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr
930 5 10
931 CCC AAG AAC CAG GAA GCC CTG CGG ATG GCC AAC 75
932 Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Asn
933 15 20 25
934 GTG GCA GAG AAC AGC AGC AGC GAC CAG AGG CAG 108
935 Val Ala Glu Asn Ser Ser Ser Asp Gln Arg Gln
936 30 35
937 GCC TGT AAG AAG CAC GAG CTG TAT GTC AGC TTC 141
938 Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe
939 40 45
940 CGA GAC CTG GGC TGG CAG GAC TGG ATC ATC GCG 174
941 Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala
942 50 55
943 CCT GAA GGC TAC GCC GCC TAC TAC TGT GAG GGG 207
944 Pro Glu Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly
945 60 65
946 GAG TGT GCC TTC CCT CTG AAC TCC TAC ATG AAC 240
947 Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn
948 70 75 80
949 GCC ACC AAC CAC GCC ATC GTG CAG ACG CTG GTC 273
950 Ala Thr Asn His Ala Ile Val Gln Thr Leu Val
951 85 90
952
953
954

955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984 CAC TTC ATC AAC CCG GAA ACG GTG CCC AAG CCC 306
985 His Phe Ile Asn Pro Glu Thr Val Pro Lys Pro
986 95 100
987 TGC TGT GCG CCC ACG CAG CTC AAT GCC ATC TCC 339
988 Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser
989 105 110
990 GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC 372
991 Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile
992 115 120
993 CTG AAG AAA TAC AGA AAC ATG GTG GTC CGG GCC 405
994 Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala
995 125 130 135
996 TGT GGC TGC CAC TAGCTCCTCC GAGAATTCAG 437
997 Cys Gly Cys His
998
999
1000 (2) INFORMATION FOR SEQ ID NO:7:
1001 (i) SEQUENCE CHARACTERISTICS:
1002 (A) LENGTH: 102 amino acids
1003 (B) TYPE: amino acid
1004 (D) TOPOLOGY: linear
1005 (ii) MOLECULE TYPE: protein
1006 (ix) FEATURE:
1007 (D) OTHER INFORMATION:

1008 wherein each Xaa independently represents one of
1009 the 20 naturally occurring L-isomer, a-amino acids.

1010
1011 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

1012
1013 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1014 1 5 10
1015 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1016 15 20
1017 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1018 25 30
1019 Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1020 35 40
1021 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1022 45 50 55

1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053

1054 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
1055 60 65
1056 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1057 70 75
1058 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1059 80 85
1060 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys

1061 90 95
1062 Xaa Cys Xaa
1063 100
1064
1065 (2) INFORMATION FOR SEQ ID NO:8:
1066 (i) SEQUENCE CHARACTERISTICS:
1067 (A) LENGTH: 97 amino acids
1068 (B) TYPE: amino acid
1069 (D) TOPOLOGY: linear
1070 (ii) MOLECULE TYPE: protein
1071 (ix) FEATURE:
1072 (D) OTHER INFORMATION:
1073 wherein each Xaa independently represents one of
1074 the 20 naturally occurring L-isomer, α -amino acids
1075
1076 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
1077
1078 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1079 1 5 10
1080 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1081 15 20
1082 Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1083 25 30
1084 Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1085 35 40
1086 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1087 45 50 55
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113

1114
1115
1116
1117
1118
1119
1120 Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa
1121 60 65
1122 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1123 70 75
1124 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1125 80 85
1126 Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa
1127 90 95
1128
1129

1130 (2) INFORMATION FOR SEQ ID NO:9:
1131 (i) SEQUENCE CHARACTERISTICS:
1132 (A) LENGTH: 136 amino acids
1133 (B) TYPE: amino acid
1134 (D) TOPOLOGY: linear
1135 (ii) MOLECULE TYPE: protein
1136 (ix) FEATURE:
1137 (A) NAME: hOP-2P
1138 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
1139

1140 Pro Leu Arg Arg Arg Gln
1141 1 5
1142 Pro Lys Lys Ser Asn Glu Leu Pro Gln
1143 10 15
1144 Ala Asn Arg Leu Pro Gly Ile Phe Asp
1145 20
1146 Asp Val Asn Gly Ser His Gly Arg Gln
1147 25 30
1148 Val Cys Arg Arg His Glu Leu Tyr Val
1149 35 40
1150 Ser Phe Gln Asp Leu Gly Trp Leu Asp
1151 45 50
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166

1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184 Tyr Val Ile Ala Pro Gln Gly Tyr Ser
1185 55 60
1186 Ala Tyr Tyr Cys Glu Gly Glu Cys Ser
1187 65
1188 Phe Pro Leu Asp Ser Cys Met Asn Ala
1189 70 75
1190 Thr Asn His Ala Ile Leu Gln Ser Leu
1191 80 85
1192 Val His Leu Met Lys Pro Asn Ala Val
1193 90 95
1194 Pro Lys Ala Cys Cys Ala Pro Thr Lys
1195 100 105
1196 Leu Ser Ala Thr Ser Val Leu Tyr Tyr
1197 110
1198 Asp Glu Ser Asn Asn Val Ile Leu Arg
1199 115 120
1200 Lys Ala Arg Asn Met Val Val Lys Ala
1201 125 130
1202 Cys Gly Cys His
1203 135
1204
1205
1206 (2) INFORMATION FOR SEQ ID NO:10:
1207 (i) SEQUENCE CHARACTERISTICS:
1208 (A) LENGTH: 133 amino acids
1209 (B) TYPE: amino acid
1210 (D) TOPOLOGY: linear
1211 (ii) MOLECULE TYPE: protein
1212 (ix) FEATURE:
1213 (A) NAME: hOP-2R
1214 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
1215
1216 Arg Arg Gln
1217 1
1218 Pro Lys Lys Ser Asn Glu Leu Pro Gln
1219 5 10

1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251 Ala Asn Arg Leu Pro Gly Ile Phe Asp
1252 15 20
1253 Asp Val Asn Gly Ser His Gly Arg Gln
1254 25 30
1255 Val Cys Arg Arg His Glu Leu Tyr Val
1256 35
1257 Ser Phe Gln Asp Leu Gly Trp Leu Asp
1258 40 45
1259 Tyr Val Ile Ala Pro Gln Gly Tyr Ser
1260 50 55
1261 Ala Tyr Tyr Cys Glu Gly Glu Cys Ser
1262 60 65
1263 Phe Pro Leu Asp Ser Cys Met Asn Ala
1264 70 75
1265 Thr Asn His Ala Ile Leu Gln Ser Leu
1266 80
1267 Val His Leu Met Lys Pro Asn Ala Val
1268 85 90
1269 Pro Lys Ala Cys Cys Ala Pro Thr Lys
1270 95 100
1271 Leu Ser Ala Thr Ser Val Leu Tyr Tyr
1272 105 110

1273 Asp Glu Ser Asn Asn Val Ile Leu Arg
1274 115 120
1275 Lys Ala Arg Asn Met Val Val Lys Ala
1276 125
1277 Cys Gly Cys His
1278 130
1279
1280

1281 (2) INFORMATION FOR SEQ ID NO:11:
1282 (i) SEQUENCE CHARACTERISTICS:
1283 (A) LENGTH: 160 amino acids
1284 (B) TYPE: amino acid
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314

1315 (D) TOPOLOGY: linear
1316 (ii) MOLECULE TYPE: protein
1317 (ix) FEATURE:
1318 (A) NAME: hOP-2S
1319 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
1320
1321 Ser Gln Gln
1322 1
1323 Pro Phe Val Val Thr Phe Phe Arg Ala
1324 5 10
1325 Ser Pro Ser Pro Ile Arg Thr Pro Arg

Patent Application US/07/099,543E

1379
1380
1381
1382 Leu Ser Ala Thr Ser Val Leu Tyr Tyr
1383 130 135
1384 Asp Glu Ser Asn Asn Val Ile Leu Arg
1385 140 145
1386 Lys Ala Arg Asn Met Val Val Lys Ala
1387 150 155
1388 Cys Gly Cys His
1389 160

LINE ERROR

ORIGINAL TEXT

24 Wrong application Serial Number
809 Response Exceeds Line Limitations
810 Response Exceeds Line Limitations
811 Response Exceeds Line Limitations
812 Response Exceeds Line Limitations
813 Response Exceeds Line Limitations
814 Response Exceeds Line Limitations
815 Response Exceeds Line Limitations
816 Response Exceeds Line Limitations
817 Response Exceeds Line Limitations
818 Response Exceeds Line Limitations
819 Response Exceeds Line Limitations
820 Response Exceeds Line Limitations
821 Response Exceeds Line Limitations
822 Response Exceeds Line Limitations

(A) APPLICATION NUMBER: US 07/599,543
at res. 19 = (Ile or Val); Xaa at res.23
Xaa at res.26 = (Ala or Ser); Xaa at res
or Ser); Xaa at res.38= (Asn or Asp); Xa
(Tyr or Cys); Xaa at res.49 = (Val or Le
res.52= (His or Asn); Xaa at res. 53 = (
Leu); Xaa at res. 54 = (Ile or Met); Xaa
or Lys); Xaa at res. 56 = (Glu, Asp or A
57=(Thr, Ala or Val); Xaa at res. 61 = (
Xaa at res. 67=(gln or Lys); Xaa at res.
(Asn or Ser); Xaa at 71=(Ile or Thr); Xa
76= (Phe or Tyr); Xaa at res. 78 = (Asp,
Xaa at res. 80= (Ser or Asn); Xaa at res
Asp); Xaa at res. 85 Arg); Xaa at res. 8
or His); and Xaa at res. 93=(Arg or Lys)

PAGE: 1

SEQUENCE MISSING ITEM REPORT
PATENT APPLICATION US/07/5 543E

DATE: 12/17/91
TIME: 13:46:34

MANDATORY IDENTIFIER THAT WAS NOT FOUND

LINE ORIGINAL TEXT

CORRECTED TEXT

76 (A) NAME: mOP2 (mature)
155 (A) NAME: mOP2
423 (A) NAME: hOP2 (mature)
535 (A) NAME: hOP2
922 (A) NAME: OP1
1137 (A) NAME: hOP-2P
1213 (A) NAME: hOP-2R
1318 (A) NAME: hOP-2S

(A) NAME/KEY: mOP2 (mature)
(A) NAME/KEY: mOP2
(A) NAME/KEY: hOP2 (mature)
(A) NAME/KEY: hOP2
(A) NAME/KEY: OP1
(A) NAME/KEY: hOP-2P
(A) NAME/KEY: hOP-2R
(A) NAME/KEY: hOP-2S